Intas
Intas Pharmaceuticals Ltd, commonly referred to as Intas, is a prominent player in the global pharmaceutical industry, headquartered in India. Established in 1977, the company has significantly expanded its operations across various regions, including Europe, the United States, and Asia. Intas focuses on the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including generic and specialty medicines, biosimilars, and over-the-counter (OTC) drugs. With a commitment to quality and innovation, Intas has achieved notable milestones, such as receiving multiple approvals from regulatory authorities worldwide. The company’s core offerings are distinguished by their affordability and accessibility, making essential healthcare solutions available to a broader audience. Intas has solidified its market position through strategic partnerships and a robust pipeline, earning recognition for its contributions to the healthcare sector.
DitchCarbon Score
How does Intas's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Intas's score of 14 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Intas's reported carbon emissions
Intas, headquartered in India, currently does not provide specific carbon emissions data or reduction targets. Without available figures, it is unclear how their emissions profile looks in terms of Scope 1, 2, or 3 emissions. However, the company is expected to align with industry standards for climate commitments, which typically include setting science-based targets and participating in global climate initiatives. As the pharmaceutical sector increasingly focuses on sustainability, Intas may be working towards establishing its climate commitments and reduction strategies in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Intas is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
